Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
| ▸ | THRA | P10827 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 4/20 | 0.50 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402978 | 0.84 | THRA (0.48) | PTGER4PTGER3PTGER2PTGER1THRA | |
| SCHEMBL27908885 | 0.84 | THRA (0.50) | PTGER4PTGER3PTGER2PTGER1THRA | |
| SCHEMBL3407137 | 0.82 | THRA (0.46) | PTGER4PTGER3PTGER2PTGER1THRA | |
| SCHEMBL23964581 | 0.78 | PTGER4 (0.60) | PTGER4PTGER3PTGER2PTGER1THRA | |
| SCHEMBL3405256 | 0.77 | THRA (0.56) | PTGER4PTGER3PTGER2PTGER1THRA | |
| SCHEMBL3407610 | 0.77 | THRA (0.43) | PTGER4PTGER3PTGER2PTGER1THRA | |
| SCHEMBL3465394 | 0.74 | CXCR5 (0.55) | THRATHRBCXCR5 | |
| SCHEMBL11587469 | 0.74 | HTR1A (0.45) | CXCR5 | |
| SCHEMBL31530600 | 0.73 | PTGER4 (0.55) | PTGER4PTGER3PTGER2PTGER1THRA | |
| SCHEMBL12760832 | 0.73 | CXCR5 (0.41) | CXCR5NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2254879-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | PTGER4 250/4885PTGER3 31/4885PTGER2 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.